> Research Use Only Disclaimer: GHRP-6 has not been approved by the FDA or any major regulatory agency for human therapeutic use. It is available only as a research chemical. This article summarizes publicly available scientific literature for educational and research purposes only. Not for human use.
---
What Is GHRP-6?
GHRP-6 (Growth Hormone-Releasing Peptide-6) is a synthetic hexapeptide ghrelin mimetic with the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂. It was the first growth hormone-releasing peptide to demonstrate robust GH-releasing activity in clinical settings, making it the prototype of an entire class of synthetic GH secretagogues that ultimately led to the discovery of ghrelin.
Developed by Cyril Y. Bowers and colleagues at Tulane University in the early 1980s, GHRP-6 emerged from a systematic modification of enkephalin analogs. While investigating whether modified opioid peptides could affect GH secretion, Bowers's group discovered that certain non-opioid-active enkephalin modifications could robustly stimulate GH release from pituitary cells — a finding that was paradoxical, since endogenous opioids suppress GH. GHRP-6 was the first hexapeptide from this program to undergo clinical evaluation, establishing the GHRP class as pharmacologically validated GH secretagogues.
Key historical milestones:
- •1982–1984: GHRP-6 identified as potent GH secretagogue by Bowers et al.
- •1991: First human clinical administration of GHRP-6 demonstrating robust GH response
- •1996: GHS-R cloned — confirming GHRP-6's molecular target (Howard et al., Science)
- •1999: Ghrelin discovered as the endogenous GHS-R ligand — retroactively making GHRP-6 a ghrelin mimetic
- •2001: Pralmorelin (GHRP-2) approved in Japan, validating the GHRP drug class
Though GHRP-6 itself was never advanced to regulatory approval, it remains one of the most widely characterized GH secretagogues in research literature, with decades of preclinical and clinical pharmacological data establishing its mechanism, dose-response relationships, and safety profile.
---
Mechanism of Action
GHS-R1a Agonism
GHRP-6 is an agonist at GHS-R1a (the canonical ghrelin/growth hormone secretagogue receptor), coupling via Gαq/PLCβ/IP₃ signaling:
1. Binding to GHS-R1a activates Gαq and phospholipase C-β
2. Phosphoinositide hydrolysis releases IP₃ (→ ER Ca²⁺ release) and DAG (→ PKC activation)
3. Intracellular Ca²⁺ rise triggers GH secretory granule exocytosis
4. Simultaneous PKC activation enhances GH gene transcription
At the hypothalamic level, GHRP-6 additionally:
- •Stimulates GHRH release from arcuate nucleus neurons
- •Inhibits somatostatin release from periventricular neurons
This dual hypothalamic-pituitary mechanism generates substantially greater GH release than could be achieved by direct pituitary action alone — the synergistic basis for GHRP+GHRH combination protocols.
The Appetite Pathway: GHS-R1a in the Hypothalamic Feeding Circuit
GHRP-6's most notable off-target effect relative to newer GHRPs is appetite stimulation, which is substantially more pronounced than with GHRP-2 or ipamorelin. This occurs via GHS-R1a in the hypothalamic arcuate nucleus:
- •NPY/AgRP neurons co-express GHS-R1a and are activated by GHRP-6
- •Activated AgRP neurons produce AGRP, which antagonizes melanocortin MC4 receptors → reduced satiety signaling
- •Simultaneous NPY release potentiates feeding behavior
- •The result is increased appetite, reduced energy expenditure, and gastric motility changes (accelerated gastric emptying)
This orexigenic effect mirrors the action of endogenous ghrelin, which is the primary circulating appetite-stimulating hormone. For research studying the ghrelin axis's role in energy metabolism, appetite regulation, or feeding behavior, GHRP-6's pronounced appetite effects make it a valuable mechanistic tool. For research primarily focused on GH/IGF-1 changes without appetite confounders, GHRP-2 or ipamorelin may be more appropriate choices.
GH/IGF-1 Downstream Effects
Following GH release triggered by GHRP-6:
- •Liver: GH receptor activation → JAK2/STAT5 signaling → IGF-1 gene transcription → IGF-1 secretion
- •Bone: IGF-1 stimulates chondrocyte proliferation and osteoblast activity
- •Muscle: GH + IGF-1 act synergistically to promote protein synthesis and satellite cell activation
- •Adipose tissue: GH promotes lipolysis; IGF-1 has anti-lipolytic counter-effects in some depots
---
Comparison: GHRP-6 vs GHRP-2 vs Ipamorelin vs Hexarelin
| Parameter | GHRP-6 | GHRP-2 | Ipamorelin | Hexarelin |
|---|---|---|---|---|
| GH potency | Moderate | High | Moderate-high | Highest |
| Appetite stimulation | Strong | Moderate | Minimal | Low-moderate |
| Cortisol elevation | Moderate | Moderate | Minimal | Low |
| Cardiac receptor binding | Low | Low | Low | High |
| Desensitization | Moderate | Moderate | Low | Higher |
| Regulatory status | Research only | Japan diagnostic | Research only | Research only |
| Cost (avg) | Low | Low-moderate | Moderate | Premium |
| Key research use | Appetite/GH coupling; ghrelin physiology | Full GHS-R1a profiling | GH-selective studies | Cardiac + GH research |
For detailed comparisons, see: GHRP-6 vs GHRP-2 comparison and Hexarelin vs GHRP-6.
---
Key Research Studies
Bowers CY 1998 — Founding GHRP Pharmacology Review (PMID 9893708)
This comprehensive review in Cell and Molecular Life Sciences documented the full GHRP pharmacological landscape, with GHRP-6 as the prototype compound. Key findings included: dose-dependent GH release, hypothalamic-pituitary dual mechanism, age-related and obesity-related blunting of GH responses, and confirmation that the GHRP receptor (GHS-R) is distinct from GHRHR. The review established GHRP-6 as the reference compound for the entire class.
Ghrelin and GHS Physiology Review (PMID 19275540)
A comprehensive review of ghrelin and growth hormone secretagogue physiology confirmed that GHRP-6 and ghrelin share the same receptor and largely overlapping downstream pharmacology. This review synthesized GHRP-6 data alongside ghrelin data to establish the integrated picture of GHS-R1a signaling in GH and appetite regulation — providing mechanistic context for interpreting GHRP-6 research data in light of the endogenous ghrelin system.
Clinical GH Response Studies
Early human studies of intravenous GHRP-6 at 1–2 μg/kg demonstrated peak GH responses of 20–50 ng/mL in healthy young adults — substantially higher than the normal physiological GH peak of 2–10 ng/mL during GH pulses. Older adults showed blunted responses (~30–50% of younger adults), consistent with somatopause-related GHS-R1a downregulation and increased somatostatin tone.
GHRP-6 in Body Composition Research
Studies in animal models demonstrated that chronic GHRP-6 administration produces significant increases in lean body mass and reductions in fat mass through combined GH-dependent and GH-independent mechanisms. The appetite-stimulating effects complicate weight management interpretations but make GHRP-6 particularly useful for muscle wasting and cachexia research models.
GHRP-6 in Synergy Stack Studies
Multiple research groups confirmed that GHRP-6 + CJC-1295 (or sermorelin) stacks produce synergistic GH release substantially exceeding either compound alone. A representative finding showed ~6.7-fold GH amplification with the combination vs ~2.1-fold for GHRP-6 alone in rat pituitary cell culture — consistent with the mechanistic synergy between GHS-R1a (Gαq) and GHRHR (Gαs) pathways. See the body composition GH research stack guide for protocol details.
---
Research Applications
GHRP-6 is used in research to study:
- •Ghrelin receptor pharmacology — as the canonical synthetic GHS-R1a agonist preceding ghrelin's discovery
- •Appetite and energy homeostasis — NPY/AgRP/AGRP circuit activation, feeding behavior in rodent models
- •GH/IGF-1 axis — dose-response studies, age-related blunting of GH responses
- •Gastric motility — GHS-R1a activation accelerates gastric emptying; relevant to motility disorder research
- •Comparison pharmacology — reference GHRP for comparing selective analogs (ipamorelin, GHRP-2)
- •Cachexia/muscle wasting models — exploring GH axis restoration in catabolic states
- •Somatopause — age-related GH secretion decline and GHRP responsiveness
---
Sourcing & Price Comparison (2026 Live Data)
GHRP-6 is among the most affordable research peptides in the GH secretagogue class due to its well-established synthesis and broad supplier availability.
| Supplier | Price/mg | Product |
|---|---|---|
| Pure Peptides UK | $1.90/mg | GHRP-6 5 mg |
| Amino Asylum | $2.00/mg | GHRP-6 5 mg |
| Ruo Bio | $2.67/mg | GHRP-6 5 mg |
| Buy Peptides USA | $3.33/mg | GHRP-6 5 mg |
| Quality Peptides | $3.83/mg | GHRP-6 5 mg |
| Wholesale Peptide | $3.83/mg | GHRP-6 5 mg |
| Biotech Peptides | $3.90/mg | GHRP-6 10 mg |
> Live pricing across all suppliers: Peptides.SO GHRP-6 peptide page. See also: GHRP-6 dosage guide and Ipamorelin vs GHRP-6 comparison.
---
Frequently Asked Questions
Q: Is GHRP-6 the same as ghrelin?
A: No, but GHRP-6 is a synthetic mimic (agonist) of ghrelin at the GHS-R1a receptor. GHRP-6 was discovered before ghrelin, and the eventual discovery of ghrelin revealed that GHRP-6 was a synthetic version of what the body produces naturally. Ghrelin has 28 amino acids and requires octanoyl acylation for receptor binding; GHRP-6 is a 6-amino-acid synthetic compound that binds the same receptor through a different structural motif.
Q: Why does GHRP-6 cause appetite stimulation?
A: GHRP-6 activates GHS-R1a receptors in the hypothalamic arcuate nucleus, where these receptors are co-expressed on NPY/AgRP neurons. Activation of these neurons releases NPY (a potent appetite stimulator) and AGRP (a melanocortin receptor antagonist that reduces satiety signaling), collectively producing strong orexigenic effects. This mirrors endogenous ghrelin's role as the primary circulating hunger signal. In research settings, appetite stimulation is often monitored as a functional endpoint confirming GHS-R1a engagement.
Q: How does GHRP-6 compare to CJC-1295 as a GH stack component?
A: CJC-1295 works via GHRHR (Gαs pathway) while GHRP-6 works via GHS-R1a (Gαq pathway). The two compounds are mechanistically complementary rather than redundant, and their combination produces synergistic GH release. CJC-1295 provides the sustained GHRH-analog stimulus; GHRP-6 amplifies pituitary responsiveness and removes somatostatin inhibition. The stack is well-characterized in research settings; see GHRP-6 stack guide.
Q: Does GHRP-6 desensitize with repeated use?
A: Some degree of GHS-R1a downregulation occurs with frequent GHRP-6 administration, though this is less pronounced than with hexarelin (the most desensitization-prone GHRP). The intermittent pulsatile dosing approach — mimicking natural ghrelin pulsatility — minimizes receptor desensitization. Most research protocols include inter-dose intervals of at least 3–4 hours to allow receptor resensitization.
Q: What are GHRP-6's effects on cortisol and prolactin?
A: GHRP-6 produces moderate elevations in cortisol (via GHS-R1a on adrenal cortex) and prolactin (via GHS-R1a on pituitary lactotrophs) alongside GH. These effects are transient and dose-dependent. For research where HPA axis activation is not desired, ipamorelin (highly selective for GH, minimal cortisol/prolactin effects) is a better choice.
Q: How does GHRP-6 affect gastric motility?
A: GHS-R1a receptors in the enteric nervous system and gastric antrum mediate accelerated gastric emptying in response to GHRP-6 and ghrelin. This prokinetic effect has been studied as a potential therapeutic application for gastroparesis and postoperative ileus in the broader ghrelin research field. In GH research protocols, the gastric motility effect is typically noted as a secondary observation rather than a primary endpoint.
---
Disclaimer
This article is for educational and research informational purposes only. GHRP-6 has not been approved by any major regulatory agency for human therapeutic use. All information reflects published scientific literature and does not constitute medical advice. Researchers should comply with all applicable regulations in their jurisdiction. For Research Use Only — Not for Human Consumption.
---
Related articles: GHRP-2 Research Profile 2026 · Hexarelin Research Profile 2026 · Ipamorelin Research Profile 2026 · GHRPs Compared